{"id":"W3135535477","doi":"10.1200/jco.2021.39.6_suppl.10","title":"KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Princess Margaret Cancer Centre; Sunnybrook Hospital","funders":"","keywords":"Medicine; Enzalutamide; Docetaxel; Prostate cancer; Abiraterone; Cohort; Prednisone; Cabazitaxel; Internal medicine; Oncology; Cancer; Adverse effect; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002036711,0.001034902,0.001122389,0.0005586442,0.0006013763,0.0009563924,0.0008746661,0.001001397,0.005419346],"category_scores_gemma":[0.00121601,0.0003682281,0.001671345,0.0004928088,0.0005145121,0.0008234704,0.0005881489,0.002502214,0.0009800363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001342463,"about_ca_system_score_gemma":0.002362689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004705886,"about_ca_topic_score_gemma":0.007359448,"domain_scores_codex":[0.999361,0.0002394001,0.00006759183,0.0001191776,0.00009017483,0.0001227479],"domain_scores_gemma":[0.9983945,0.0001568499,0.0003800357,0.0002025627,0.0001590431,0.0007069532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7751644,0.04127721,0.04067802,0.001080727,0.003999679,0.000470944,0.0003134058,0.002101368,0.01821589,0.0003217514,0.02071979,0.09565685],"study_design_scores_gemma":[0.4596595,0.3741779,0.126831,0.0002520827,0.002312942,0.001098617,0.0001963616,0.001104724,0.006849901,0.0003880902,0.02703587,0.00009305321],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9661515,0.003505515,0.0007895314,0.0005411259,0.0001707051,0.004626602,0.01928486,0.00009465241,0.004835472],"genre_scores_gemma":[0.952064,0.002158662,0.002573635,0.001341214,0.0003145649,0.003353424,0.03326926,0.00003806848,0.004887064],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005419346,"threshold_uncertainty_score":0.01812953,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1396881840877597,"score_gpt":0.450521152236118,"score_spread":0.3108329681483583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}